Details of the Drug Reposition

General Information of This Drug (ID: DM3RZ9H)

• Drug Name: Vemircopan (DM3RZ9H)
• Synonyms: Vemircopan; Vemircopan [INN]; 2086178-00-7; ACH-5228; ACH-0145228; HN6I4K50QB; 2-Azabicyclo(3.1.0)hexane-3-carboxamide, 2-(2-(3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methyl-2-pyridinyl)-5-methyl-, (1R,3S,5R)-; 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-3-methyl-2-pyridinyl)-5-methyl-, (1R,3S,5R)-; VEMIRCOPAN [USAN]; UNII-HN6I4K50QB; CFD-IN-1; ALXN2050; CHEMBL4650325; SCHEMBL18578125; ALXN-2050; BDBM386545; GLXC-25930; US10287301, Compound 485; AKOS040757250; MS-30630; CS-0213583; ALXN2050; ACH 0145228; ACH-5228; (1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H-indazol- 1-yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide; (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo(3.1.0)hexane-3-carboxamide; (1R,3S,5R)-2-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide; (1R,3S,5R)-2-{[3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
• Drug Type: Small molecule

Information on Drug Reposition of This Drug

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Paroxysmal nocturnal haemoglobinuria	DISBHMYH	3A21.0	Phase 2	[1]
Proliferative lupus nephritis	DISVVCXG	4A40	Phase 2	[2]
Generalized myasthenia gravis	DISQOYF5	8C60	Phase 2	[3]
IgA nephropathy	DISZ8MTK	MF8Y	Phase 2	[2]

References

• [1] ClinicalTrials.gov (NCT04170023) A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients as Monotherapy. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05097989) A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05218096) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis. U.S.National Institutes of Health.